THU0617 Work Productivity and Daily Activity in Patients with Rheumatoid Arthritis in Four Phase III Randomized Clinical Trials of Baricitinib

BackgroundBaricitinib (bari), an oral JAK1 and JAK2 inhibitor, was efficacious in Ph 3 studies in patients (pts) with active RA.1–4ObjectivesTo assess effects of bari on workplace and daily activity with the Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire in ad...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.416
Hauptverfasser:	Smolen, J.S., DeLozier, A.M., de Bono, S., Yang, L., Gaich, C.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!